This segment focuses on the development of novel biologic therapeutics for the treatment of various cancers. Key research and development activities include preclinical studies and clinical trials for candidates like INBRX-109, a tetravalent agonist of death receptor 5, which is being evaluated in Phase 2 trials for chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma. The segment also explores innovative approaches such as hexavalent agonists of OX40 (INBRX-106) for a range of oncology indications. Technologies employed include protein engineering and antibody development. The goal is to provide targeted treatments that improve patient outcomes and address unmet needs in cancer therapy. Future opportunities involve expanding the pipeline with novel targets and combination therapies, while navigating regulatory pathways for drug approval.

This segment is dedicated to developing biologic therapies for rare diseases with significant unmet medical needs. A key asset in this area was INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which was in Phase 1 clinical trials for the treatment of patients with AAT deficiency before being sold to Sanofi. Research efforts focus on protein engineering to enhance the efficacy and safety of biologic drugs. The segment aims to improve the quality of life for patients with rare genetic disorders by providing targeted therapies that address the underlying causes of these conditions. Future opportunities include identifying new targets for rare diseases and developing innovative delivery methods to enhance drug bioavailability and patient compliance. Regulatory considerations are paramount, with a focus on obtaining orphan drug designation and navigating the approval process for rare disease therapies.